Medicare and Medicaid will continue to pay for Avastin prescribed for breast cancer even though the drug offers no meaningful benefits — certainly none worth $88,000 per patient per year to taxpayers. It will be hard to control the Medicare entitlement if snake oil is to be made available on demand.